Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
申请人:Bayer Pharma Aktiengesellschaft
公开号:US08084481B2
公开(公告)日:2011-12-27
The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮,其生产过程,它们的单独或组合使用用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病的药物。